Skip to main content
Zealand Pharma logo

Zealand Pharma — Investor Relations & Filings

Ticker · ZEAL ISIN · DK0060257814 LEI · 549300ITBB1ULBL4CZ12 CO Professional, scientific and technical activities
Open in API
Filings indexed 1,531 across all filing types
Latest filing 2020-11-20 Share Issue/Capital Cha…
Country DK Denmark
Listing CO ZEAL

About Zealand Pharma

https://www.zealandpharma.com/

Zealand Pharma is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. The company's primary focus is on advancing treatments for obesity and metabolic diseases, with a strategic goal to become a leader in this field. Its pipeline includes multiple candidates targeting obesity, such as petrelintide (a long-acting amylin analog) and survodutide (a glucagon/GLP-1 dual agonist licensed to a partner). Beyond metabolic health, Zealand Pharma develops therapies for rare diseases, including dasiglucagon for congenital hyperinsulinism and glepaglutide for short bowel syndrome. The company also has programs in chronic inflammation. Leveraging its expertise in peptide science, the company aims to create next-generation therapeutics to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Zealand Pharma increases its share capital as a consequence of exercise of employee warrants
Share Issue/Capital Change Classification · 98% confidence The document is a company announcement from Zealand Pharma regarding an increase in share capital due to the exercise of employee warrants. While it details the capital change, it is a formal announcement of the event rather than a standalone share issuance prospectus or a complex financial report. According to the 'Menu vs Meal' rule, since the document is relatively short and includes an 'Attachment' link to the full announcement/filing, it is classified as a Report Publication Announcement (RPA).
2020-11-20 English
Share Issue/Capital Change 2020
Share Issue/Capital Change Classification · 99% confidence The document is titled "Zealand Pharma increases its share capital as a consequence of exercise of employee warrants" and details the issuance of 15,995 new shares due to warrant exercises, resulting in a capital increase of DKK 2,196,298.50. It explicitly mentions amendments to the company's Articles of Association to reflect this change. This action directly relates to changes in the company's capital structure and share count resulting from financing/incentive schemes. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not a general earnings release (ER), a full annual report (10-K), or a simple announcement of a report (RPA).
2020-11-20 English
Zealand Pharma continues to advance clinical programs and commercial launch capabilities and presents financial results for the first nine months of 2020
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report for 9M 2020' and contains detailed financial results, business highlights, pipeline updates, and financial guidance for the first nine months of 2020. It provides substantive financial data and analysis, fitting the definition of an Interim/Quarterly Report (IR). 9M 2020
2020-11-12 English
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report for 9M 2020' and contains detailed financial results, business highlights, and pipeline updates for the first nine months of the fiscal year. It provides substantive financial data (revenue, operating expenses, cash position) and management analysis, fitting the definition of an Interim/Quarterly Report (IR). 9M 2020
2020-11-12 English
Total number of shares and voting rights in Zealand Pharma at September 30, 2020
Share Issue/Capital Change Classification · 95% confidence The document is a regulatory announcement regarding the total number of shares and voting rights in Zealand Pharma as of September 30, 2020. This is a standard disclosure required by Danish law when there are changes to share capital. While it mentions share capital, it is not a primary issuance or a transaction in own shares (buyback), but rather a periodic disclosure of the current capital structure. As it does not fit into specific categories like SHA or POS, and is a standard regulatory disclosure, it is best classified as a Regulatory Filing (RNS).
2020-09-30 English
Share Issue/Capital Change 2020
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Correction: Zealand Pharma announces amendments to its Articles of Association following the granting of warrants'. It explicitly details changes made to the company's Articles of Association due to the issuance of employee warrants, referencing specific article numbers (Article 8.7, Article 19) and dates of board approval (September 14, 2020). This action—amending foundational corporate documents like the Articles of Association, often triggered by capital structure changes like warrant grants—is a significant corporate governance event. While it relates to capital (warrants), the core action is the formal amendment of the governing rules. This type of filing, which updates the company's internal structure and rules following a specific corporate action, aligns best with Governance Information (CGR), as it directly modifies the company's foundational charter. It is not a general financing announcement (CAP), nor is it a standard regulatory filing (RNS) or a report announcement (RPA).
2020-09-22 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.